Please try another search
Gamida Cell Ltd. researches, develops, and commercializes cell therapies. The company offers Omisirge (omidubicel-onlv), a cell therapy for use in treatment of patients with hematologic malignancies and severe aplastic anemia. Its product candidate includes GDA-201, an investigational NK cell-based cancer immunotherapy, for the treatment of hematologic and solid tumors, as well as to treat follicular and diffuse large B-cell lymphomas which is in phase 1 of phase1/2 clinical trial. The company was incorporated in 1998 and is based in Boston, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Julian Adams | 69 | 2016 | Director |
Kenneth I. Moch | 69 | 2016 | Independent Director |
Shawn Cline Tomasello | 65 | 2019 | Independent Chairwoman |
Ivan M. Borrello | 59 | 2022 | Independent Director |
Stephen T. Wills | 67 | 2019 | Independent Director |
Abigail L. Jenkins | 48 | 2022 | President, CEO & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review